Quick Answer
Eton Pharmaceuticals, Inc. reported Gross Profit of $42.74 million for the year ending 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +82.6% in Gross Profit from 2024 to 2025.
- This data is from Eton Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $500.0 thousand | Q1 2020: -$3.0 thousand | Q2 2020: -$8.0 thousand | Q3 2020: -$17.0 thousand | Q1 2021: $10.31 million | Q2 2021: $2.89 million | Q3 2021: $121.0 thousand | Q1 2022: $1.33 million | Q2 2022: $4.61 million | Q3 2022: $2.02 million | Q1 2023: $3.35 million | Q2 2023: $9.68 million | Q3 2023: $4.40 million | Q1 2024: $5.01 million | Q2 2024: $5.63 million | Q3 2024: $6.30 million | Q1 2025: $9.86 million | Q2 2025: $11.92 million | Q3 2025: $7.86 million.
- Over the full 7 years of available data (2019 to 2025), Eton Pharmaceuticals, Inc.'s Gross Profit has grown by 8,346.6%.
- Historical annual values: Fiscal year 2025: $42.74 million | Fiscal year 2024: $23.41 million | Fiscal year 2023: $21.06 million | Fiscal year 2022: $14.32 million | Fiscal year 2021: $19.01 million | Fiscal year 2020: -$397.0 thousand | Fiscal year 2019: $506.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: